Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Avidity Biosciences (RNA) Other Non Operating Income (2020 - 2025)

Avidity Biosciences (RNA) has disclosed Other Non Operating Income for 6 consecutive years, with -$477000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Other Non Operating Income fell 337.31% year-over-year to -$477000.0, compared with a TTM value of -$1.9 million through Dec 2025, down 683.47%, and an annual FY2025 reading of -$1.9 million, down 683.47% over the prior year.
  • Other Non Operating Income was -$477000.0 for Q4 2025 at Avidity Biosciences, down from -$380000.0 in the prior quarter.
  • Across five years, Other Non Operating Income topped out at $201000.0 in Q4 2024 and bottomed at -$651000.0 in Q2 2025.
  • Average Other Non Operating Income over 5 years is -$145200.0, with a median of -$73500.0 recorded in 2021.
  • The sharpest move saw Other Non Operating Income crashed 8000.0% in 2023, then soared 291.43% in 2024.
  • Year by year, Other Non Operating Income stood at -$46000.0 in 2021, then soared by 60.87% to -$18000.0 in 2022, then crashed by 483.33% to -$105000.0 in 2023, then skyrocketed by 291.43% to $201000.0 in 2024, then crashed by 337.31% to -$477000.0 in 2025.
  • Business Quant data shows Other Non Operating Income for RNA at -$477000.0 in Q4 2025, -$380000.0 in Q3 2025, and -$651000.0 in Q2 2025.